Takeda, a pharmaceutical company, has developed an innovative sugar-lowering drug that is a combination of alogliptin and metformin. The representatives of the company already announced that the new drug was launched in the Russian market. The medicine is especially effective in cases when the monotherapy has lost its effectiveness.
During 2-year long observation, the combined use of alogliptin, a highly selective inhibitor of dipeptidyl peptidase-4, and metformin provided a longer and more stable glycemic control comparing to the combination of metformin and sulfonylurea. According to researchers, the combination of metformin and DPP-4 delivers maximum clinical benefit, as it enhances the effect of lowering the blood glucose level, reduces the risk of hypoglycemia, stabilizes body weight, and preserves multiple effects of metformin.
In the Russian market the drug will be available in tablet form which, according to Dmitry Koloda, the Medical Director of Takeda Russia, will ensure the ease of its administration and significantly improve patient’s compliance with the therapy. This is a key factor for successful treatment of that disease. It is well known that the main cause of treatment failure (75% of cases) is the poor adherence of patients to the treatment due to the difficulty of drug administration.